{"id":5886,"date":"2025-10-29T15:58:07","date_gmt":"2025-10-29T13:58:07","guid":{"rendered":"https:\/\/www.msd.ch\/fr\/?post_type=story&p=5886"},"modified":"2025-10-29T15:58:51","modified_gmt":"2025-10-29T13:58:51","slug":"ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon","status":"publish","type":"story","link":"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/","title":{"rendered":"Ce que nous faisons pour soutenir le mois de sensibilisation au cancer du poumon"},"content":{"rendered":"\n
\n
\n \n \n Responsabilit\u00e9<\/small>\n <\/a>\n \n \n

\n Ce que nous faisons pour soutenir le mois de sensibilisation au cancer du poumon\n <\/h1>\n

Novembre est le mois de la sensibilisation au cancer du poumon. Un mois d\u00e9di\u00e9 aux personnes touch\u00e9es par le cancer du poumon et \u00e0 la sensibilisation du public aux causes, \u00e0 la d\u00e9tection pr\u00e9coce et \u00e0 la pr\u00e9vention de la maladie. Saviez-vous que le cancer du poumon est la premi\u00e8re cause de d\u00e9c\u00e8s par cancer dans le monde? Chez MSD, nous nous engageons \u00e0 lutter contre le cancer du poumon et \u00e0 am\u00e9liorer les soins contre le cancer. D\u00e9couvrez comment nous soutenons le mois de sensibilisation au cancer du poumon.<\/p>\n <\/div>\n\n

\n

29.10.2025<\/p>\n

\n

Share this article<\/p>\n

\n \nFacebook icon<\/title><\/svg>\n<\/a><\/p>\n

\n\n\n\n\t.st0{fill:#00857C;}\n\n\nX icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nLinkedin icon<\/title><\/svg>\n<\/a><\/p>\n

\n \nEmail icon<\/title><\/svg>\n<\/a><\/p>\n <\/div>\n <\/div>\n\n
\n
\n
\n \n \n \n \n \"Lung\n <\/picture>\n\n <\/figure>\n \n <\/div>\n <\/div>\n\n
\n
\n
\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n\n\n\n
<\/div>\n\n\n\n

En Suisse, environ 4 900 personnes re\u00e7oivent chaque ann\u00e9e un diagnostic de cancer du poumon et environ 3 300 en meurent. La plupart des patients nouvellement diagnostiqu\u00e9s sont \u00e2g\u00e9s de plus de 50 ans au moment du diagnostic. En g\u00e9n\u00e9ral, le cancer du poumon ne provoque pas de sympt\u00f4mes avant de s’\u00eatre propag\u00e9. Pour cela le cancer du poumon est souvent diagnostiqu\u00e9 \u00e0 un stade tardif. Si le cancer s’est d\u00e9j\u00e0 propag\u00e9 en dehors des poumons, le pronostic des patients est tr\u00e8s mauvais. Gr\u00e2ce \u00e0 de nouveaux traitements efficaces, cette situation est en train de changer. Beaucoup de gens pensent qu’un diagnostic de cancer du poumon est une condamnation \u00e0 mort. Cependant, au cours de la derni\u00e8re d\u00e9cennie, de nouvelles avanc\u00e9es ont \u00e9t\u00e9 r\u00e9alis\u00e9es, ce qui a conduit \u00e0 un plus grand nombre de survivants et \u00e0 plus d’espoir pour les personnes confront\u00e9es \u00e0 la maladie.<\/p>\n\n\n\n

\u201cChez MSD, nous sommes solidaires des personnes touch\u00e9es et nous continuons \u00e0 faire pression pour que des progr\u00e8s soient r\u00e9alis\u00e9s dans le domaine des soins contre le cancer<\/em><\/em>.” <\/em><\/p>\n\n\n\n

Malgr\u00e9 la fr\u00e9quence du cancer du poumon, de nombreuses id\u00e9es fausses circulent encore sur cette maladie. <\/strong>C’est pourquoi nous soutenons diverses initiatives de sensibilisation.<\/p>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

Site web pour les patients atteints de cancer du poumon<\/h4>\n\n\n\n

Le site web dans le portail des patient(e)s MSD fournit des informations d\u00e9taill\u00e9es sur les principaux types de cancer du poumon, les options de diagnostic et de traitement, les r\u00e9ponses aux questions les plus fr\u00e9quentes et des informations sur les endroits o\u00f9 les patients peuvent obtenir des conseils et du soutien. En outre, les patients atteints de cancer du poumon peuvent t\u00e9l\u00e9charger diverses listes de contr\u00f4le contenant des questions pour les aider \u00e0 pr\u00e9parer leur prochain rendez-vous chez le m\u00e9decin.<\/p>\n\n\n\n

D\u00e9couvrez le portail des patients MSD<\/strong><\/u><\/a><\/p>\n<\/div>\n\n\n\n

\n
\"Image<\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n
\n
\n
\"Photo<\/figure>\n<\/div>\n\n\n\n
\n

LuftiBus<\/h4>\n\n\n\n

De nombreuses maladies pulmonaires se d\u00e9veloppent sans \u00eatre remarqu\u00e9es – un d\u00e9pistage pr\u00e9coce peut faire toute la diff\u00e9rence. La pr\u00e9vention commence par l’information. C’est pourquoi MSD soutient le LuftiBus et LUNGE Z\u00fcrich \u2013 en tant que sponsor principal en 2025. Les visiteurs du LuftiBus peuvent s’informer sur les maladies respiratoires, le d\u00e9pistage pr\u00e9coce et la sant\u00e9 pulmonaire, et effectuer gratuitement un contr\u00f4le des poumons.
Chez MSD, nous sommes fiers de soutenir cette initiative en tant que sponsor, car la pr\u00e9vention est un \u00e9l\u00e9ment central de la promotion de la sant\u00e9.<\/p>\n<\/div>\n<\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
\n

Test pulmonaire en ligne<\/h4>\n\n\n\n

Dans de nombreux cas, le cancer du poumon n’est d\u00e9couvert qu’\u00e0 un stade avanc\u00e9. Cela peut \u00eatre d\u00fb au fait que ses signes et sympt\u00f4mes sont \u00e9galement observ\u00e9s dans d’autres maladies et ne sont pas imm\u00e9diatement associ\u00e9s au cancer du poumon.

Connaissez-vous les sympt\u00f4mes du cancer du poumon? Avez-vous des sympt\u00f4mes que vous devriez faire examiner par un m\u00e9decin?<\/p>\n\n\n\n

Testez votre fonction pulmonaire en ligne!<\/strong><\/a><\/p>\n<\/div>\n\n\n\n

\n
\"Image:<\/a><\/figure>\n<\/div>\n<\/div>\n\n\n\n
<\/div>\n\n\n\n

Faits sur le cancer du poumon que vous devriez savoir<\/h2>\n\n\n\n

Le cancer du poumon est le troisi\u00e8me type de cancer le plus fr\u00e9quent en Suisse. Chaque ann\u00e9e, environ 4 900 personnes sont nouvellement diagnostiqu\u00e9es et environ 3 300 en meurent. Tout le monde peut avoir un cancer du poumon, mais le risque augmente si vous avez plus de 50 ans et si vous fumez actuellement ou avez fum\u00e9 dans le pass\u00e9. Ne pas fumer est la mesure la plus importante pour pr\u00e9venir le cancer du poumon.<\/p>\n\n\n\n

Le cancer du poumon n’est pas une condamnation \u00e0 mort.<\/strong> Il existe plusieurs options de traitement, mais la d\u00e9tection pr\u00e9coce est essentielle et peut sauver des vies. Si vous souffrez d’une toux persistante inexpliqu\u00e9e pendant plus de trois semaines ou d’un essoufflement, consultez votre m\u00e9decin!<\/p>\n\n\n\n

<\/div>\n\n\n\n

\u00c0 propos de notre recherche clinique en oncologie<\/h2>\n\n\n\n

Saviez-vous que MSD g\u00e8re l\u2019un des programmes de recherche clinique en oncologie les plus importants et les plus dynamiques au monde? Il comprend actuellement plus de 1600 \u00e9tudes cliniques. La Suisse fait partie de ce programme de recherche. Notre \u00e9quipe coordonne actuellement 36 essais cliniques dans diff\u00e9rents cancers (\u00e9tat: 07\/2025). MSD est \u00e9galement l\u2019une des principales entreprises dans la recherche de vaccins contre les maladies \u00e9vitables, comme le cancer du col de l\u2019ut\u00e9rus et d\u2019autres cancers li\u00e9s au VPH. En Suisse, nous collaborons avec divers partenaires pour faire progresser les solutions innovantes dans le traitement du cancer. Ces derni\u00e8res ann\u00e9es, nous avons apport\u00e9 une contribution importante \u00e0 l\u2019am\u00e9lioration des options de traitement pour les patient(e)s atteints de cancer.<\/p>\n\n\n\n

Pour en savoir plus sur notre travail, cliquez ici<\/a>.<\/p>\n\n\n\n


<\/p>\n\n\n\n

CH-NON-01949, 10\/2025<\/sup><\/p>\n","protected":false},"excerpt":{"rendered":"

En Suisse, environ 4 900 personnes re\u00e7oivent chaque ann\u00e9e un diagnostic de cancer du poumon et environ 3 300 en meurent. La plupart des patients nouvellement diagnostiqu\u00e9s sont \u00e2g\u00e9s de plus de 50 ans au moment du diagnostic. En g\u00e9n\u00e9ral, le cancer du poumon ne provoque pas de sympt\u00f4mes avant de s’\u00eatre propag\u00e9. Pour cela […]<\/p>\n","protected":false},"featured_media":5887,"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[25],"content_topic":[18],"admin_field":[],"class_list":["post-5886","story","type-story","status-publish","has-post-thumbnail","hentry","tag-oncology","content_topic-responsibility"],"yoast_head":"\nCe que nous faisons pour soutenir le mois de sensibilisation au cancer du poumon - msd.ch<\/title>\n<meta name=\"description\" content=\"Chez MSD, nous nous engageons \u00e0 lutter contre le cancer du poumon et \u00e0 am\u00e9liorer les soins contre le cancer. D\u00e9couvrez comment nous soutenons le mois de sensibilisation au cancer du poumon.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD soutient le mois de sensibilisation au cancer du poumon\" \/>\n<meta property=\"og:description\" content=\"Chez MSD, nous nous engageons \u00e0 lutter contre le cancer du poumon et \u00e0 am\u00e9liorer les soins contre le cancer. D\u00e9couvrez comment nous soutenons le mois de sensibilisation au cancer du poumon.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-29T13:58:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2022\/11\/MSD2730-Bild-Lung-Cancer-Awareness-1920x1080-V02.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"MSD soutient le mois de sensibilisation au cancer du poumon\" \/>\n<meta name=\"twitter:description\" content=\"Chez MSD, nous nous engageons \u00e0 lutter contre le cancer du poumon et \u00e0 am\u00e9liorer les soins contre le cancer. D\u00e9couvrez comment nous soutenons le mois de sensibilisation au cancer du poumon.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2022\/11\/MSD2730-Bild-Lung-Cancer-Awareness-1920x1080-V02.png\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/\",\"url\":\"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/\",\"name\":\"Ce que nous faisons pour soutenir le mois de sensibilisation au cancer du poumon - msd.ch\",\"isPartOf\":{\"@id\":\"https:\/\/www.msd.ch\/fr\/#website\"},\"datePublished\":\"2025-10-29T13:58:07+00:00\",\"dateModified\":\"2025-10-29T13:58:51+00:00\",\"description\":\"Chez MSD, nous nous engageons \u00e0 lutter contre le cancer du poumon et \u00e0 am\u00e9liorer les soins contre le cancer. D\u00e9couvrez comment nous soutenons le mois de sensibilisation au cancer du poumon.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Stories\",\"item\":\"https:\/\/www.msd.ch\/fr\/stories-archive\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ce que nous faisons pour soutenir le mois de sensibilisation au cancer du poumon\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.msd.ch\/fr\/#website\",\"url\":\"https:\/\/www.msd.ch\/fr\/\",\"name\":\"msd.ch\",\"description\":\"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s'engagent dans ce sens.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.msd.ch\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ce que nous faisons pour soutenir le mois de sensibilisation au cancer du poumon - msd.ch","description":"Chez MSD, nous nous engageons \u00e0 lutter contre le cancer du poumon et \u00e0 am\u00e9liorer les soins contre le cancer. D\u00e9couvrez comment nous soutenons le mois de sensibilisation au cancer du poumon.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/","og_locale":"en_US","og_type":"article","og_title":"MSD soutient le mois de sensibilisation au cancer du poumon","og_description":"Chez MSD, nous nous engageons \u00e0 lutter contre le cancer du poumon et \u00e0 am\u00e9liorer les soins contre le cancer. D\u00e9couvrez comment nous soutenons le mois de sensibilisation au cancer du poumon.","og_url":"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/","og_site_name":"msd.ch","article_modified_time":"2025-10-29T13:58:51+00:00","og_image":[{"width":1920,"height":1080,"url":"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2022\/11\/MSD2730-Bild-Lung-Cancer-Awareness-1920x1080-V02.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"MSD soutient le mois de sensibilisation au cancer du poumon","twitter_description":"Chez MSD, nous nous engageons \u00e0 lutter contre le cancer du poumon et \u00e0 am\u00e9liorer les soins contre le cancer. D\u00e9couvrez comment nous soutenons le mois de sensibilisation au cancer du poumon.","twitter_image":"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2022\/11\/MSD2730-Bild-Lung-Cancer-Awareness-1920x1080-V02.png","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/","url":"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/","name":"Ce que nous faisons pour soutenir le mois de sensibilisation au cancer du poumon - msd.ch","isPartOf":{"@id":"https:\/\/www.msd.ch\/fr\/#website"},"datePublished":"2025-10-29T13:58:07+00:00","dateModified":"2025-10-29T13:58:51+00:00","description":"Chez MSD, nous nous engageons \u00e0 lutter contre le cancer du poumon et \u00e0 am\u00e9liorer les soins contre le cancer. D\u00e9couvrez comment nous soutenons le mois de sensibilisation au cancer du poumon.","breadcrumb":{"@id":"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.msd.ch\/fr\/stories\/ce-que-nous-faisons-pour-soutenir-le-mois-de-sensibilisation-au-cancer-du-poumon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Stories","item":"https:\/\/www.msd.ch\/fr\/stories-archive\/"},{"@type":"ListItem","position":2,"name":"Ce que nous faisons pour soutenir le mois de sensibilisation au cancer du poumon"}]},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/fr\/#website","url":"https:\/\/www.msd.ch\/fr\/","name":"msd.ch","description":"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s'engagent dans ce sens.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"acf":[],"extended_data":{"featured_image":"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2022\/11\/MSD2730-Bild-Lung-Cancer-Awareness-1920x1080-V02.png?w=1024","acf_fields":{"mco_page_tracking_data":"","page_text_direction_selection":"ltr","show_section":true,"related_content_section_heading":"","story_one_selection":"select","related_content_item_one":{"ID":1433,"post_author":"974","post_date":"2026-02-20 12:55:17","post_date_gmt":"2026-02-20 10:55:17","post_content":"<!-- wp:acf\/hero-block {\"name\":\"acf\/hero-block\",\"data\":{\"mco_hero_block_tagline_text\":\"\",\"_mco_hero_block_tagline_text\":\"mco_hero_block_tagline_text\",\"mco_hero_block_ttle\":\"Oncologie\",\"_mco_hero_block_ttle\":\"mco_hero_block_title\",\"mco_hero_block_description\":\"Nous travaillons \u00e0 inventer un monde o\u00f9 le cancer n\u2019est pas seulement trait\u00e9, mais gu\u00e9ri \u2013 et o\u00f9 certains types peuvent m\u00eame \u00eatre emp\u00each\u00e9s d\u00e8s le d\u00e9part.\",\"_mco_hero_block_description\":\"mco_hero_block_description\",\"mco_hero_block_image_url\":1940,\"_mco_hero_block_image_url\":\"mco_hero_block_image_url\",\"mcc_hero_block_primary_image_alt\":\"\",\"_mcc_hero_block_primary_image_alt\":\"mcc_hero_block_primary_image_alt_text\",\"mco_hero_block_image_small_url\":\"\",\"_mco_hero_block_image_small_url\":\"mco_hero_block_image_small_url\",\"mcc_hero_block_secondary_image_alt\":\"\",\"_mcc_hero_block_secondary_image_alt\":\"mcc_hero_block_secondary_image_alt_text\",\"mco_hero_block_button_cta\":\"\",\"_mco_hero_block_button_cta\":\"mco_hero_block_button_cta\",\"hero_video_type\":\"youtube\",\"_hero_video_type\":\"hero_video_type\",\"youtube_video_url\":\"\",\"_youtube_video_url\":\"youtube_video\",\"video_accessible_name\":\"\",\"_video_accessible_name\":\"testimonial_video_accessible_name\",\"b2_hero_block_lazy_load_image\":\"0\",\"_b2_hero_block_lazy_load_image\":\"b2_hero_block_lazy_load_image_key\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Notre mission est de proposer de nouvelles innovations qui prolongent et am\u00e9liorent la vie des personnes atteintes de cancer.\",\"_title\":\"mco_title_block_title\",\"description\":\"\\u003cdiv id=\\u0022mco-title-block-block_5e9de3bc8282f\\u0022 class=\\u0022mco-title-block msdberg-block mb-2 aligncenter\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022wrapper\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022mco-title-block-content\\u0022\\u003e\\r\\n\\r\\nNous travaillons \u00e0 pr\u00e9venir le cancer gr\u00e2ce \u00e0 des vaccins pr\u00e9ventifs et \u00e0 proposer aux oncologues des traitements qui offrent \u00e0 leurs patient(e)s une meilleure qualit\u00e9 de vie et plus de temps.\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\nChacun de nous conna\u00eet quelqu'un qui a \u00e9t\u00e9 touch\u00e9 par le cancer. Lorsqu'un diagnostic de cancer est pos\u00e9, l'important n'est pas de savoir quelle sera la prochaine avanc\u00e9e scientifique, mais quand elle sera disponible pour les patient(e)s en Suisse.\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Notre travail en oncologie\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"edit\",\"className\":\"pull-up-stats negative mb-2\"} \/-->\n\n<!-- wp:group {\"className\":\"stat-group mb-2\"} -->\n<div class=\"wp-block-group stat-group mb-2\"><!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"31\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"essais cliniques concernant nos m\u00e9dicaments anti-cancer en Suisse (en 01\/2026).\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\",\"className\":\"mb-2\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"~250\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"patients sont actuellement inscrits dans nos essais cliniques en Suisse et environ 120 patients sont activement sous traitement avec le m\u00e9dicament \u00e0 l'\u00e9tude (en 01\/2026).\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\",\"className\":\"mb-2\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"\\u0026gt;15\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"types de cancer diff\u00e9rents sont analys\u00e9s dans nos \u00e9tudes cliniques en Suisse (en 01\/2026).\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\",\"className\":\"mb-2\"} \/--><\/div>\n<!-- \/wp:group -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"32%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:32%\"><!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Notre objectif<\/h2>\n<!-- \/wp:heading --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:paragraph -->\n<p>Notre entreprise a une longue histoire de d\u00e9veloppement de m\u00e9dicaments innovants. Dans le domaine de l'oncologie, nous nous concentrons sur l\u2019immunoth\u00e9rapie, qui vise \u00e0 activer le propre syst\u00e8me immunitaire de l\u2019organisme pour combattre la tumeur. Notre engagement continu \u00e0 l\u2019\u00e9gard de la recherche et du d\u00e9veloppement nous a permis d\u2019\u00e9tablir un programme de recherche exceptionnellement vaste, comprenant environ 1600 \u00e9tudes cliniques. La Suisse fait partie de ce programme, et m\u00e8ne actuellement 37 <a href=\"https:\/\/www.msd.ch\/fr\/home\/research\/clinical-trials\/clinical-trials-in-switzerland\/\" target=\"_blank\" rel=\"noreferrer noopener\">\u00e9tudes cliniques<\/a> dans different types de tumeurs (en 01\/2026). Aujourd\u2019hui, notre portefeuille comprend les m\u00e9dicaments oncologiques qui traitent diff\u00e9rents cancers et pathologies li\u00e9es au traitement du cancer.<\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"32%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:32%\"><!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Acc\u00e8s aux soins<\/h2>\n<!-- \/wp:heading --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:paragraph -->\n<p>Am\u00e9liorer l\u2019acc\u00e8s aux soins contre le cancer est notre priorit\u00e9 strat\u00e9gique. Nous travaillons avec l\u2019ensemble des experts en oncologie pour aider les patients \u00e0 avoir acc\u00e8s aux m\u00e9dicaments oncologiques dont ils ont besoin et pour \u00e9tendre l\u2019offre de soins de qualit\u00e9 contre le cancer.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p>L\u2019\u00e9quipe suisse d\u2019oncologie<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li>collabore avec les autorit\u00e9s et les institutions afin de garantir l\u2019acc\u00e8s \u00e0 nos m\u00e9dicaments.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>travaille sur des solutions visant \u00e0 am\u00e9liorer continuellement le soutien aux m\u00e9decins et aux patients dans le traitement du cancer.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>interagit avec les oncologues, les sommit\u00e9s scientifiques et les organisations de patients pour avoir un aper\u00e7u du march\u00e9 et des besoins des clients.<\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li>s'informe et se concerte avec les d\u00e9cideurs lorsqu'il s'agit d'organiser les soins contre le cancer en Suisse de mani\u00e8re encore plus efficace et orient\u00e9e vers les solutions.<\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:spacer {\"height\":\"30px\"} -->\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:heading -->\n<h2 class=\"wp-block-heading\">Des progr\u00e8s gr\u00e2ce aux partenariats<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column {\"width\":\"66.66%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:66.66%\"><!-- wp:paragraph -->\n<p>Nous travaillons avec tous les acteurs du domaine des soins du cancer: les parties prenantes, les prestataires de services de sant\u00e9, les partenaires gouvernementaux et industriels. Tous ceux qui partagent notre mission de prolonger et d'am\u00e9liorer la vie des personnes atteintes de cancer.<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:paragraph -->\n<p><strong>Nos priorit\u00e9s:<\/strong><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column {\"width\":\"33.33%\"} -->\n<div class=\"wp-block-column\" style=\"flex-basis:33.33%\"><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":6791,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-full is-resized\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2023\/06\/education.png\" alt=\"Icon education\" class=\"wp-image-6791\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"level\":4} -->\n<h4 class=\"wp-block-heading\">Information et expertise<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Nous mettons \u00e0 disposition sur diff\u00e9rentes plates-formes des informations sur les maladies canc\u00e9reuses, la pr\u00e9vention et le d\u00e9pistage, les options th\u00e9rapeutiques et des indications sur les lieux o\u00f9 les personnes concern\u00e9es peuvent obtenir conseil et soutien: pour les patient(e)s atteints de cancer et leurs proches ainsi que pour les professionnels de la sant\u00e9 :<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li><strong>mon-immunoth\u00e9rapie:<\/strong><br><a href=\"http:\/\/www.mon-immunotherapie\/\" target=\"_blank\" rel=\"noreferrer noopener\">pour les patient(e)s sous immunoth\u00e9rapie<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>MSD Sant\u00e9<\/strong>: <a href=\"https:\/\/www.msd-gesundheit.ch\/fr\" target=\"_blank\" rel=\"noreferrer noopener\">plateforme d'information pour les patient(e)s atteint(e)s de cancer et leurs proches<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>mymsd.ch<\/strong>: <a href=\"https:\/\/www.mymsd.ch\/fr\" target=\"_blank\" rel=\"noreferrer noopener\">plateforme d'information pour les professionnel(le)s de la sant\u00e9<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>My Survival Story: <\/strong><a href=\"https:\/\/www.mysurvivalstory.org\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">Plateforme destin\u00e9e aux personnes concern\u00e9(e)s ayant surmont\u00e9 leur cancer<\/a><\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":6793,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-full is-resized\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2023\/06\/Prevention.png\" alt=\"Icon prevention\" class=\"wp-image-6793\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"level\":4} -->\n<h4 class=\"wp-block-heading\">Pr\u00e9vention et d\u00e9pistage pr\u00e9coce<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Nous collaborons avec diff\u00e9rentes organisations de patients et soutenons des campagnes de sensibilisation de la population \u00e0 la pr\u00e9vention et au d\u00e9pistage du cancer:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li><strong>Derma2go<\/strong>:\u00a0<a href=\"https:\/\/www.derma2go.com\/de\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">service suisse de t\u00e9l\u00e9d\u00e9rmatologie permettant de faire \u00e9valuer en ligne des probl\u00e8mes de peau par des m\u00e9decins sp\u00e9cialistes et d\u2019obtenir rapidement un diagnostic fond\u00e9<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Vivre avec un cancer du poumon:\u00a0<\/strong><a href=\"https:\/\/www.vivre-avec-le-cancer-du-poumon.ch\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">plateforme destin\u00e9e aux patient(e)s atteint(e)s d\u2019un cancer du poumon et \u00e0 leurs proches<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>PINK CUBE Test Your Breast:<\/strong>\u00a0<a href=\"https:\/\/www.pinkcube-testyourbreast.ch\/\" target=\"_blank\" rel=\"noreferrer noopener\">initiative visant \u00e0 renforcer la pr\u00e9vention et le d\u00e9pistage pr\u00e9coce du cancer du sein<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>SSDV\u00a0<\/strong>Soci\u00e9t\u00e9 Suisse de Dermatologie et V\u00e9n\u00e9r\u00e9ologie: <a href=\"https:\/\/www.derma.swiss\/fr\/patients\/campagne-nationale-contre-le-cancer-de-la-peau\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">campagne nationale de pr\u00e9vention du cancer de la peau<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Association pour la recherche sur le cancer de la peau<\/strong>:<a href=\"https:\/\/www.skincancer.ch\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\"> engag\u00e9e dans la recherche, la pr\u00e9vention et la sensibilisation au cancer de la peau<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Association pulmonaire de Zurich<\/strong>: <a href=\"https:\/\/lunge-zuerich.ch\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">soutient les personnes atteint(e)s de maladies pulmonaires, informe sur la sant\u00e9 pulmonaire et s\u2019engage en faveur de la pr\u00e9vention et du d\u00e9pistage pr\u00e9coce<\/a>.<\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":6796,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"full\",\"linkDestination\":\"none\"} -->\n<figure class=\"wp-block-image size-full is-resized\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2023\/06\/Cancer-care.png\" alt=\"Icon Cancer Care\" class=\"wp-image-6796\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"level\":4} -->\n<h4 class=\"wp-block-heading\">Am\u00e9lioration de la prise en charge du cancer<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph -->\n<p>Nous soutenons les plateformes qui font avancer en permanence les discussions sur la politique de la sant\u00e9 visant \u00e0 am\u00e9liorer la prise en charge du cancer en Suisse:<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:list -->\n<ul class=\"wp-block-list\"><!-- wp:list-item -->\n<li><strong>gfs .bern:<\/strong>\u00a0<br><a href=\"https:\/\/www.msd.ch\/fr\/news\/le-deuxieme-moniteur-de-prise-en-charge-du-cancer-en-suisse-montre-limportance-capitale-du-depistage-du-cancer-et-du-traitement-precoce\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">enqu\u00eates r\u00e9guli\u00e8res aupr\u00e8s de la population sur la qualit\u00e9 des soins en mati\u00e8re de cancer en Suisse<\/a><br><br><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Oncosuisse:<\/strong> Nous sommes membres du pool de partenaires Oncosuisse et encourageons ainsi activement la mise en r\u00e9seau des parties prenantes dans le domaine de la prise en charge du cancer, dont <a href=\"https:\/\/oncosuisse.ch\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">l'objectif est de supprimer les barri\u00e8res dans le syst\u00e8me et de combler les lacunes<\/a>.\u00a0<strong><br><br><\/strong><\/li>\n<!-- \/wp:list-item -->\n\n<!-- wp:list-item -->\n<li><strong>Schweizerisches Konsumentenforum kf: <\/strong> des OncoRoundtables sont r\u00e9guli\u00e8rement organis\u00e9es avec diff\u00e9rents acteurs pour discuter et trouver des solutions afin d'am\u00e9liorer les soins actuels contre le cancer en Suisse.<br><br><\/li>\n<!-- \/wp:list-item --><\/ul>\n<!-- \/wp:list --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:acf\/testimonials-block {\"name\":\"acf\/testimonials-block\",\"data\":{\"media_placement\":\"left\",\"_media_placement\":\"testimonials_block_media_placement\",\"testimonials_posts\":[\"7911\"],\"_testimonials_posts\":\"testimonials_block_posts\"},\"mode\":\"preview\",\"className\":\"mb-1\"} \/-->\n\n<!-- wp:heading {\"textAlign\":\"center\"} -->\n<h2 class=\"wp-block-heading has-text-align-center\"><br>Domaines principaux de th\u00e9rapie<\/h2>\n<!-- \/wp:heading -->\n\n<!-- wp:spacer {\"height\":\"30px\"} -->\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n<!-- \/wp:spacer -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7922,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2024\/11\/oncology_bowel.png?w=200\" alt=\"Ic\u00f4ne: Cancer colorectal\" class=\"wp-image-7922\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cancer colorectal<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/cancer-colorectal\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/gastrointestinal-cancers\/colorectal\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":8467,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2025\/08\/Icon-Magenkrebs1.png?w=1164\" alt=\"\" class=\"wp-image-8467\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cancer de l'estomac<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/cancer-de-lestomac\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/gastrointestinal-cancers\/gastric\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7920,\"width\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2024\/11\/Prostate-Cancer-Icon.png?w=161\" alt=\"Ic\u00f4ne: Cancer de la prostate\" class=\"wp-image-7920\" style=\"width:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cancer de la prostate<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/cancer-de-la-prostate\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patients<\/a><br><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7916,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2024\/11\/oncology_headneck1.png?w=200\" alt=\"Ic\u00f4ne: Cancer de la t\u00eate et du cou\" class=\"wp-image-7916\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cancer de la t\u00eate et du cou<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/cancer-de-la-tete-et-du-cou\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/head-and-neck-squamous-cell-carcinoma\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7925,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2024\/11\/oncology_bladder.png?w=200\" alt=\"Ic\u00f4ne: Cancer de la vessie\" class=\"wp-image-7925\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cancer de la vessie<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/cancer-de-la-vessie\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/genitourinary-cancers\/uc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":8933,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2026\/01\/Icon_Biliary-Cancer.png?w=240\" alt=\"Ic\u00f4ne : cancer de la v\u00e9sicule biliaire et cancer des voies biliaires\" class=\"wp-image-8933\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cancer de la v\u00e9sicule<br>et des voies biliaires<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/cancer-de-la-vesicule-et-des-voies-biliaires\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/gastrointestinal-cancers\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7918,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2024\/11\/Keytruda_cervical-cancer_icon_msd_green-1.png?w=608\" alt=\"Ic\u00f4ne: Cancer du col\/du corps de l'ut\u00e9rus\" class=\"wp-image-7918\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cancer du col de l\u2019ut\u00e9rus<br>Cancer du corps de l'ut\u00e9rus<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/gyn-cancers\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7921,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2024\/11\/oncology_lung.png?w=200\" alt=\"Ic\u00f4ne: Cancer du poumon\" class=\"wp-image-7921\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cancer du poumon<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/cancer-du-poumon\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/tc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7926,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2024\/11\/oncology_kidney.png?w=200\" alt=\"Ic\u00f4ne: Cancer du rein\" class=\"wp-image-7926\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cancer du rein<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/cancer-du-rein\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/genitourinary-cancers\/rcc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7919,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2024\/11\/Breast_icon-002.png?w=1163\" alt=\"Ic\u00f4ne: Cancer du sein\" class=\"wp-image-7919\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Cancer du sein<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/cancer-du-sein\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/tnbc\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7924,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2024\/11\/oncology_lymphoma.png?w=200\" alt=\"Ic\u00f4ne: Lymphome hodgkinien\" class=\"wp-image-7924\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">Lymphome hodgkinien<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/fr\/cancer\/lymphome-hodgkinien\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/classical-hodgkin-lymphoma\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column -->\n\n<!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":7923,\"width\":\"100px\",\"height\":\"100px\",\"sizeSlug\":\"large\",\"linkDestination\":\"none\",\"align\":\"center\",\"className\":\"is-style-default\"} -->\n<figure class=\"wp-block-image aligncenter size-large is-resized is-style-default\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2024\/11\/oncology_melanoma.png?w=200\" alt=\"Ic\u00f4ne: M\u00e9lanome\" class=\"wp-image-7923\" style=\"width:100px;height:100px\"\/><\/figure>\n<!-- \/wp:image -->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":4} -->\n<h4 class=\"wp-block-heading has-text-align-center\">M\u00e9lanome<\/h4>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\",\"fontSize\":\"small\"} -->\n<p class=\"has-text-align-center has-small-font-size\"><a href=\"https:\/\/www.msd-gesundheit.ch\/fr\/cancer\/melanome\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les patient(e)s<\/a><br><a href=\"https:\/\/www.mymsd.ch\/fr\/products\/keytruda\/indications\/melanom\/\" target=\"_blank\" rel=\"noreferrer noopener\">Informations pour les professionnels de la sant\u00e9<\/a><\/p>\n<!-- \/wp:paragraph --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"En savoir plus sur notre engagement dans la lutte contre le cancer\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"edit\",\"className\":\"mt-2\"} \/-->\n\n<!-- wp:acf\/featured-stories-block-e1 {\"name\":\"acf\/featured-stories-block-e1\",\"data\":{\"content_selection\":\"manual\",\"_content_selection\":\"mco_featured_stories_e1_block_content_selection\",\"story_one\":6452,\"_story_one\":\"mco_featured_stories_e1_block_story_one\",\"story_two\":7421,\"_story_two\":\"mco_featured_stories_e1_block_story_two\",\"story_three\":6886,\"_story_three\":\"mco_featured_stories_e1_block_story_three\",\"story_four\":6152,\"_story_four\":\"mco_featured_stories_e1_block_story_four\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p><sup>CH-NON-00473, 02\/2026<\/sup><\/p>\n<!-- \/wp:paragraph -->","post_title":"Oncologie","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"oncology","to_ping":"","pinged":"","post_modified":"2026-02-20 12:55:29","post_modified_gmt":"2026-02-20 10:55:29","post_content_filtered":"","post_parent":25,"guid":"https:\/\/vip2-msd.com\/germany\/?page_id=1433","menu_order":0,"post_type":"page","post_mime_type":"","comment_count":"0","filter":"raw"},"story_two_selection":"select","related_content_item_two":false,"story_three_selection":"select","related_content_item_three":{"ID":2759,"post_author":"974","post_date":"2026-03-31 21:14:27","post_date_gmt":"2026-03-31 19:14:27","post_content":"<!-- wp:acf\/hero-block {\"name\":\"acf\/hero-block\",\"data\":{\"mco_hero_block_tagline_text\":\"\",\"_mco_hero_block_tagline_text\":\"mco_hero_block_tagline_text\",\"mco_hero_block_ttle\":\"\u00c9tudes cliniques de MSD en Suisse\",\"_mco_hero_block_ttle\":\"mco_hero_block_title\",\"mco_hero_block_description\":\"\\u0022Les \u00e9tudes cliniques sont la cl\u00e9 des nouvelles connaissances en termes de diagnostic et de traitement des maladies. Nous sommes fiers d\u2019y contribuer en Suisse.\\u0022\\r\\n\\r\\n\\u003cem\\u003eKlaudia Georgi, Sr. Director Clinical Research MSD Switzerland \\u0026amp; Serbia\\u003c\/em\\u003e\",\"_mco_hero_block_description\":\"mco_hero_block_description\",\"mco_hero_block_image_url\":2760,\"_mco_hero_block_image_url\":\"mco_hero_block_image_url\",\"mcc_hero_block_primary_image_alt\":\"\",\"_mcc_hero_block_primary_image_alt\":\"mcc_hero_block_primary_image_alt_text\",\"mco_hero_block_image_small_url\":\"\",\"_mco_hero_block_image_small_url\":\"mco_hero_block_image_small_url\",\"mcc_hero_block_secondary_image_alt\":\"\",\"_mcc_hero_block_secondary_image_alt\":\"mcc_hero_block_secondary_image_alt_text\",\"mco_hero_block_button_cta\":{\"title\":\"Connaissances de base sur les \u00e9tudes cliniques\",\"url\":\"https:\/\/www.msd.ch\/fr\/home\/research\/clinical-trials\/\",\"target\":\"\"},\"_mco_hero_block_button_cta\":\"mco_hero_block_button_cta\",\"mco_hero_block_button_cta_aria_label\":\"\",\"_mco_hero_block_button_cta_aria_label\":\"mco_hero_block_button_cta_aria_label\",\"hero_video_type\":\"youtube\",\"_hero_video_type\":\"hero_video_type\",\"youtube_video_url\":\"\",\"_youtube_video_url\":\"youtube_video\",\"video_accessible_name\":\"\",\"_video_accessible_name\":\"testimonial_video_accessible_name\",\"b2_hero_block_lazy_load_image\":\"0\",\"_b2_hero_block_lazy_load_image\":\"b2_hero_block_lazy_load_image_key\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:acf\/title-block {\"name\":\"acf\/title-block\",\"data\":{\"title\":\"Notre travail en chiffres\",\"_title\":\"mco_title_block_title\",\"description\":\"\",\"_description\":\"mco_title_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_title_block_content_label\",\"cta_one\":\"\",\"_cta_one\":\"mco_title_block_cta_one\",\"cta_two\":\"\",\"_cta_two\":\"mco_title_block_cta_two\",\"image\":\"\",\"_image\":\"mco_title_block_image\"},\"align\":\"center\",\"mode\":\"preview\",\"className\":\"pull-up-stats negative mb-2\"} \/-->\n\n<!-- wp:group -->\n<div class=\"wp-block-group\"><!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"40\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"essais cliniques en cours en Suisse\\r\\n(\u00e9tat 01\/2026)\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"10\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"m\u00e9dicaments et vaccins de MSD, premiers de la classe th\u00e9rapeutique, enregistr\u00e9s en Suisse depuis 2010\\r\\n(\u00e9tat 01\/2026)\\r\\n\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/statistics-block {\"name\":\"acf\/statistics-block\",\"data\":{\"stat_statistic\":\"173\",\"_stat_statistic\":\"stat_block_statistic\",\"stat_caption\":\"\",\"_stat_caption\":\"stat_block_caption\",\"stat_description\":\"millions de francs suisses investis dans la recherche depuis 2012\\r\\n(\u00e9tat: 01\/2026)\\r\\n\",\"_stat_description\":\"stat_block_description\",\"stat_cta\":\"\",\"_stat_cta\":\"stat_block_cta_link\"},\"mode\":\"edit\"} \/--><\/div>\n<!-- \/wp:group -->\n\n<!-- wp:acf\/content-block {\"name\":\"acf\/content-block\",\"data\":{\"maintain_image_aspect_ratio\":\"0\",\"_maintain_image_aspect_ratio\":\"content_block_maintain_image_aspect_ratio\",\"negative_style\":\"0\",\"_negative_style\":\"content_block_negative\",\"content_selection\":\"static\",\"_content_selection\":\"content_selction_method\",\"content_block_image\":9165,\"_content_block_image\":\"content_block_image\",\"content_block_heading\":\"La recherche clinique de MSD Suisse est coordonn\u00e9e depuis notre site de la R\u00f6sslimatt, \u00e0 Lucerne.\",\"_content_block_heading\":\"content_block_heading\",\"heading_level\":\"h3\",\"_heading_level\":\"content_block_heading_level\",\"content_block_body\":\"\",\"_content_block_body\":\"content_block_body\",\"content_block_cta\":{\"title\":\"Nos filiales\",\"url\":\"https:\/\/www.msd.ch\/fr\/home\/about-us\/sites\/\",\"target\":\"_blank\"},\"_content_block_cta\":\"content_block_cta\",\"content_block_aria_label\":\"\",\"_content_block_aria_label\":\"content_block_aria_label\",\"content_block_cta_button_style\":\"\",\"_content_block_cta_button_style\":\"content_block_cta_button_style_cf4f3fd32dc26ec4ba7a6c14e51289c8\",\"content_block_optional_cta\":\"\",\"_content_block_optional_cta\":\"content_block_optional_cta\",\"content_block_optional_cta_aria_label\":\"\",\"_content_block_optional_cta_aria_label\":\"content_block_optional_cta_aria_label\",\"content_block_optional_cta_button_style\":\"\",\"_content_block_optional_cta_button_style\":\"content_block_optional_cta_button_style_d7b3517ac72218a3fb8daa4bc7def7a4\",\"content_block_optional_tag\":\"\",\"_content_block_optional_tag\":\"content_block_optional_tag\",\"content_block_video\":\"\",\"_content_block_video\":\"content_block_video\",\"content_media_position\":\"left\",\"_content_media_position\":\"content_media_position\",\"brightcove_account_id\":\"\",\"_brightcove_account_id\":\"bright_cove_account_id\",\"content_block_video_accessible_name\":\"\",\"_content_block_video_accessible_name\":\"content_block_video_accessible_name\",\"content_block_play_button_accessible_name\":\"\",\"_content_block_play_button_accessible_name\":\"content_block_play_button_accessible_name\",\"content_block_popup_accessible_name\":\"\",\"_content_block_popup_accessible_name\":\"content_block_popup_accessible_name\",\"content_block_popup_close_button_accessible_name\":\"\",\"_content_block_popup_close_button_accessible_name\":\"content_block_popup_close_button_accessible_name\"},\"mode\":\"preview\"} \/-->\n\n<!-- wp:heading {\"textAlign\":\"center\",\"level\":1} -->\n<h1 class=\"wp-block-heading has-text-align-center\">Le programme d\u2019\u00e9tudes cliniques de MSD en Suisse (\u00e9tat 01\/2026)<\/h1>\n<!-- \/wp:heading -->\n\n<!-- wp:paragraph {\"align\":\"center\"} -->\n<p class=\"has-text-align-center\">(publi\u00e9 sur <a href=\"http:\/\/www.clinicaltrials.gov\/\">www.clinicaltrials.gov<\/a>)<\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:columns -->\n<div class=\"wp-block-columns\"><!-- wp:column -->\n<div class=\"wp-block-column\"><!-- wp:image {\"id\":8918,\"sizeSlug\":\"full\",\"linkDestination\":\"none\",\"className\":\"mb-2\"} -->\n<figure class=\"wp-block-image size-full mb-2\"><img src=\"https:\/\/www.msd.ch\/fr\/wp-content\/uploads\/sites\/87\/2026\/01\/2026-01-MSD-Carte-Programme-Etudes-Cliniques-Suisse_v2.png\" alt=\"Carte: Sites des \u00e9tudes cliniques de MSD Suisse (\u00e9tat 01\/2026)\" class=\"wp-image-8918\"\/><\/figure>\n<!-- \/wp:image --><\/div>\n<!-- \/wp:column --><\/div>\n<!-- \/wp:columns -->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Dans le domaine de l'immunologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Tout ouvrir\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Tout fermer\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Maladie intestinale\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-7240-001 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Ulcerative Colitis\\r\\n\\r\\nStudy centers: Bern, St. Gallen, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-7240-008 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants with Moderately to Severely Active Crohn\u2019s Disease\\r\\n\\r\\nStudy centers: Basel, Bern, St. Gallen, Zurich\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Dans le domaine de l'infectiologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Tout ouvrir\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Tout fermer\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"VIH\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-8527-011 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nPhase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis\\r\\n\\r\\nStudy centers: Basel, Bern, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-8591A-051 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\nA Phase 3, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in Participants With HIV-1 Who Are Virologically Suppressed on Antiretroviral Therapy\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, Lausanne, Lugano, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cstrong\\u003eMK-8591A-053 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine\/Islatravir (DOR\/ISL 100 mg\/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Na\u00efve Participants\\r\\n\\r\\nStudy centers: Basel, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-8591A-054 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Open-label Clinical Study of Doravirine\/Islatravir (DOR\/ISL [100 mg\/0.25 mg]) Once Daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR\/ISL (100 mg\/0.75 mg) QD in a Phase 3 Clinical Study\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, St. Gallen, Lugano, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cstrong\\u003eMK-8591B-060 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2b, Randomized, Active-Controlled, Open-Label Clinical Study to Evaluate a Switch to Islatravir (ISL) and Ulonivirine (ULO) Once-Weekly in Adults with HIV-1 Virologically Suppressed on Bictegravir\/Emtricitabine\/Tenofovir Alafenamide (BIC\/FTC\/TAF) Once-Daily\\r\\n\\r\\nStudy centers: Basel, Bern, Geneva, Lugano\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\",\"className\":\"mt-2\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Dans le domaine de la m\u00e9decine g\u00e9n\u00e9rale\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Tout ouvrir\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Tout fermer\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Maladie pulmonaire\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-5475-013 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2a Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-5475 in Adults With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease\\r\\n\\r\\nStudy centers: St. Gallen, Zurich, Basel\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-7962-038 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nAn Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH\\r\\n\\r\\nStudy center: Zurich\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":1,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:acf\/b6-accordion-list {\"name\":\"acf\/b6-accordion-list\",\"data\":{\"mco_b6_accordion_list_tagline\":\"\",\"_mco_b6_accordion_list_tagline\":\"mco_b6_accordion_list_tagline_6947uhf9ywhuj\",\"mco_b6_accordion_list_title\":\"Dans le domaine de l'oncologie\",\"_mco_b6_accordion_list_title\":\"mco_b6_accordion_list_title_6947uhf9ywhuj\",\"mco_b6_accordion_type\":\"multiple\",\"_mco_b6_accordion_type\":\"mco_b6_accordion_type_6947uhf9ywhuj\",\"mco_b6_accordion_list_collapse_button\":\"1\",\"_mco_b6_accordion_list_collapse_button\":\"mco_b6_accordion_expand_all_6947uhf9ywhuj\",\"mco_b6_accordion_expand_all\":\"Tout ouvrir\",\"_mco_b6_accordion_expand_all\":\"mco_b6_accordion_expand_all\",\"mco_b6_accordion_close_all\":\"Tout fermer\",\"_mco_b6_accordion_close_all\":\"mco_b6_accordion_close\",\"mco_b6_accordion_add_faq\":\"1\",\"_mco_b6_accordion_add_faq\":\"mco_b6_accordion_add_faq\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"Cancer de l\u2019estomac\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_0_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-1022-011 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Geneva, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003e\\u003cstrong\\u003eMK-5909-005 \u2013 recruitment open\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\nA Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Basel, Zurich, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-9999-U02A \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Substudy of the MK-9999-U02 Master Protocol to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers\\r\\n\\r\\nStudy centers: Bellinzona, Geneva\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_0_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_summary\":\"Cancer de l'\u0153sophage\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_1_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-3475-06B \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1\/PD-L1 Treatment: Substudy 06B.\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06C \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable\/ Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06D \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced\/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06E \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable\/Metastatic Esophageal Cancer: Substudy 06E\\r\\n\\r\\nStudy centers: Chur, Geneva\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-06F \u2013 Study in start-up \\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2 Open-Label, Umbrella Platform Design Study of Investigational Agent(s) in Participants With 2L\/3L Unresectable Locally Advanced or Metastatic Esophageal Cancer: Substudy 06F\\r\\n\\r\\nStudy centers: Chur, Geneva\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_1_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_summary\":\"Cancer de la prostate\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_2_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2400-001 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)\\r\\n\\r\\nStudy centers: Aarau, Basel, Fribourg, Geneva, Zurich\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_2_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_summary\":\"Cancer de la t\u00eate et du cou\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_3_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-689\/KEYNOTE-689 - recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Geneva\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_3_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_summary\":\"Cancer de la vessie\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_4_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_details\":\"\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-676\/KEYNOTE-676 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Bacillus Calmette-Guerin (BCG) in Participants with High-risk Non-muscle Invasive Bladder Cancer (HRNMIBC) that is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Basel, Geneva, Zurich\\u003c\/p\\u003e\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_4_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_summary\":\"Cancer du poumon\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_5_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-1084-007 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed\/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)\\r\\n\\r\\nStudy centers: Fribourg, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-019 \u2013 \\u003cspan class=\\u0022gray_text\\u0022\\u003erecruitment open\\u003c\/span\\u003e\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab with or without MK-2870 in Resectable Stages II-IIIB (N2) NSCLC for participants not achieving pCR after Receiving Neoadjuvant Pembrolizumab with Platinum-based Doublet Chemotherapy Followed by Surgery\\r\\n\\r\\nStudy centers: Lausanne, Fribourg, Frauenfeld, Chur\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-091\/KEYNOTE-091 -\u00a0\\u003cspan class=\\u0022gray_text\\u0022\\u003eoutsourced - recruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Basel, Bellinzona, Bern, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-B98 - recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 1b\/2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1\/L1-refactory Extensive Stage Small Cell Lung Cancer in Need of Second-Line Therapy\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: St. Gallen\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_5_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_summary\":\"Cancer du rein (Carcinome r\u00e9nal)\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_6_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_details\":\"\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-6482-011 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAn Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1\/L1 Therapy\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Bellinzona, Chur, Geneva, Zurich\\u003c\/p\\u003e\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_6_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_summary\":\"Cancer du sang (Tumeurs malignes h\u00e9matologiques)\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_7_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-1026-003 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies\\r\\n\\r\\nStudy centers: Bellinzona, Bern\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2140-010 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)\\r\\n\\r\\nStudy centers: Baden, Bellinzona, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-4280A-008 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician\u2019s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)\\r\\n\\r\\nStudy centers: Bellinzona\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_7_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_summary\":\"Cancer du sein\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_8_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2870-010 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nAn Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician`s Choice in Participants with HR+\/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer\\r\\n\\r\\nStudy centers: Basel, Thun, Zurich\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-012 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician\u2019s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery\\r\\n\\r\\nStudy centers: Chur, Fribourg, Geneva, Thun, Zurich\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_8_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_summary\":\"Cancers gyn\u00e9cologiques\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_9_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_details\":\"\\u003cstrong\\u003eMK-2870-005 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy\\r\\n\\r\\nStudy centers: Bern, Bellinzona, Chur, Basel\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-020 \u2013 recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician\u2019s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer\\r\\n\\r\\nStudy centers: Basel, Bern\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-2870-021 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021\/ENGOTov85\/GOG-3102)\\r\\n\\r\\nStudy centers: Bern, Bellinzona, Chur, Geneva, Winterthur\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_9_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_summary\":\"M\u00e9lanome\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_10_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-054 \/ KEYNOTE-054 - \\u003cspan class=\\u0022gray_text\\u0022\\u003eoutsourced - recruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAdjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Geneva, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-3475-716\/KEYNOTE-716 - \\u003cspan class=\\u0022green_text\\u0022\\u003erecruitment closed\\u003c\/span\\u003e\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eAdjuvant Therapy with Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy centers: Bellinzona, Bern, Chur, Geneva, Lausanne, Sion, St. Gallen, Zurich\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_10_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_summary\":\"Tumeurs solides\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_summary\":\"mco_b6_accordion_list_row_summary_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_heading\":\"h5\",\"_mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_heading\":\"mcc_b6_accordion_list_custom_headings\",\"mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_anchor_id\":\"\",\"_mco_b6_accordion_list_row_11_mcc_b6_accordion_custom_anchor_id\":\"mcc_b6_accordion_list_custom_id\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_details\":\"\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-0472-001 \u2013 recruitment open\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1\/1b Open-label, Multicenter Clinical Study of MK-0472 as Monotherapy and Combination Therapy in Participants with Advanced\/Metastatic Solid Tumors.\\r\\n\\r\\nStudy centers: Geneva, Bellinzona, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-1084-001 - recruitment open\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\nA Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors\\r\\n\\r\\nStudy centers: Bellinzona, St. Gallen\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u0026nbsp;\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003e\\u003cstrong\\u003eMK-3475-587\/KEYNOTE-587 - recruitment closed\\u003c\/strong\\u003e\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eLong-term Safety and Efficacy Extension Study for Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Basel, Geneva, Zurich\\u003c\/p\\u003e\\r\\n\\u0026nbsp;\\r\\n\\r\\n\\u003cstrong\\u003eMK-4884-001 \u2013 Study in start-up\\u003c\/strong\\u003e\\r\\n\\r\\nA Phase 1 Open-label Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants with Advanced Solid Tumors\\r\\n\\r\\nStudy centers: Bellinzona, Lausanne, St. Gallen\\r\\n\\r\\n\\u0026nbsp;\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\r\\n\\u003cstrong\\u003eMK-7339-002 - recruitment closed\\u003c\/strong\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003cdiv class=\\u0022col s12\\u0022\\u003e\\r\\n\\u003cp class=\\u0022col l9 m9 s12\\u0022\\u003eA Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer\\u003c\/p\\u003e\\r\\n\\u003cp class=\\u0022col l2 m2 offset-l1 offset-m1 s12\\u0022\\u003eStudy center: Bellinzona\\u003c\/p\\u003e\\r\\n\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\\r\\n\\u003c\/div\\u003e\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_details\":\"mco_b6_accordion_list_row_details_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_image\":\"\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_image\":\"mco_b6_accordion_list_row_image_6947uhf9ywhuj\",\"mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_open\":\"0\",\"_mco_b6_accordion_list_row_11_mco_b6_accordion_list_row_open\":\"mco_b6_accordion_list_row_open_6947uhf9ywhuj\",\"mco_b6_accordion_list_row\":12,\"_mco_b6_accordion_list_row\":\"mco_b6_accordion_list_row_6947uhf9ywhuj\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p>Aper\u00e7u des \u00e9tudes men\u00e9es dans toute la Suisse qui recherchent des participants: <a href=\"https:\/\/www.humanforschung-schweiz.ch\/fr\/\" target=\"_blank\" rel=\"noreferrer noopener nofollow\">www.humanforschung-schweiz.ch<\/a><\/p>\n<!-- \/wp:paragraph -->\n\n<!-- wp:acf\/featured-banner-block {\"name\":\"acf\/featured-banner-block\",\"data\":{\"mco_featured_banner_negative\":\"1\",\"_mco_featured_banner_negative\":\"mco_featured_banner_negative_294ytohe\",\"image\":2806,\"_image\":\"mco_featured_banner_block_image\",\"image_alt_text\":\"\",\"_image_alt_text\":\"mco_featured_banner_block_image_alt_text\",\"title\":\"Nous aimerions redonner espoir aux personnes victimes d\u2019un cancer\",\"_title\":\"mco_featured_banner_block_title\",\"description\":\"Nous investissons dans le d\u00e9veloppement de m\u00e9dicaments oncologiques innovateurs pour aider les personnes victimes d\u2019une maladie canc\u00e9reuse.\",\"_description\":\"mco_featured_banner_block_description\",\"content_label\":\"\",\"_content_label\":\"mco_featured_banner_block_content_label\",\"cta_one\":{\"title\":\"En savoir plus\",\"url\":\"https:\/\/www.msd.ch\/fr\/home\/about-us\/areas-of-focus\/oncology\/\",\"target\":\"_blank\"},\"_cta_one\":\"mco_featured_banner_block_cta_one\",\"cta_one_aria_label\":\"\",\"_cta_one_aria_label\":\"mco_featured_banner_block_cta_one_aria_label_dIweyH6epdW9l52\",\"cta_two\":\"\",\"_cta_two\":\"mco_featured_banner_block_cta_two\"},\"mode\":\"edit\"} \/-->\n\n<!-- wp:paragraph -->\n<p><sup>CH-NON-00136, 03\/2026<\/sup><\/p>\n<!-- \/wp:paragraph -->","post_title":"\u00c9tudes cliniques de MSD en Suisse","post_excerpt":"","post_status":"publish","comment_status":"closed","ping_status":"closed","post_password":"","post_name":"clinical-trials-in-switzerland","to_ping":"","pinged":"","post_modified":"2026-03-31 21:14:37","post_modified_gmt":"2026-03-31 19:14:37","post_content_filtered":"","post_parent":8833,"guid":"https:\/\/vip2-msd.com\/switzerland\/?page_id=2759","menu_order":0,"post_type":"page","post_mime_type":"","comment_count":"0","filter":"raw"},"scroll-to-top":false,"subheader_title":"Novembre est le mois de la sensibilisation au cancer du poumon. Un mois d\u00e9di\u00e9 aux personnes touch\u00e9es par le cancer du poumon et \u00e0 la sensibilisation du public aux causes, \u00e0 la d\u00e9tection pr\u00e9coce et \u00e0 la pr\u00e9vention de la maladie. Saviez-vous que le cancer du poumon est la premi\u00e8re cause de d\u00e9c\u00e8s par cancer dans le monde? Chez MSD, nous nous engageons \u00e0 lutter contre le cancer du poumon et \u00e0 am\u00e9liorer les soins contre le cancer. D\u00e9couvrez comment nous soutenons le mois de sensibilisation au cancer du poumon.","secondary_image":false,"video_hosting_selection":"youtube","youtube_url":"","primary_cta":"Read more","secondary_cta":"","mcc_page_job_number":"","show_image_captions":false,"heading_level":"","related_content_item_one_aria_label":"","related_content_item_three_aria_label":"","video_accessible_name":"","primary_cta_aria_label":"","secondary_cta_aria_label":""}},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/story\/5886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/story"}],"about":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/types\/story"}],"version-history":[{"count":28,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/story\/5886\/revisions"}],"predecessor-version":[{"id":8609,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/story\/5886\/revisions\/8609"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/media\/5887"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/media?parent=5886"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/tags?post=5886"},{"taxonomy":"content_topic","embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/content_topic?post=5886"},{"taxonomy":"Admin Field","embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/admin_field?post=5886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}